Received: from westeu12-emailsignatures-cloud.codetwo.com (13.93.42.39) by AM1PEPF000252DF.mail.protection.outlook.com (10.167.16.57) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9891.9 via Frontend Transport; Tue, 5 May 2026 09:57:20 +0000 Received: from AM1PEPF000252DF.eurprd07.prod.outlook.com (2603:10a6:20b:313:cafe::27) by AS8PR04CA0066.outlook.office365.com (2603:10a6:20b:313::11) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.20.9870.25 via Frontend Transport; Tue, 5 May 2026 09:57:21 +0000 Received: from GV1PR07CU001.outbound.protection.outlook.com (40.93.214.99) by westeu12-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Tue, 05 May 2026 09:57:20 +0000 Received: from GV1PR02MB8353.eurprd02.prod.outlook.com ([fe80::bac:5de1:56c4:91ac]) by GV1PR02MB8353.eurprd02.prod.outlook.com ([fe80::bac:5de1:56c4:91ac%3]) with mapi id 15.20.9870.023; Tue, 5 May 2026 09:57:14 +0000 Received: from GV1PR02MB8353.eurprd02.prod.outlook.com (2603:10a6:150:54::21) by AM7PPF718F66E3E.eurprd02.prod.outlook.com (2603:10a6:20f:fff1::811) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9870.27; Tue, 5 May 2026 09:57:14 +0000 Received: from PAWPR02MB11137.eurprd02.prod.outlook.com (2603:10a6:102:46b::17) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Tue, 5 May 2026 09:57:29 +0000 Received: from AS8PR04CA0066.eurprd04.prod.outlook.com (2603:10a6:20b:313::11) by PAWPR02MB11137.eurprd02.prod.outlook.com (2603:10a6:102:46b::17) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9870.25; Tue, 5 May 2026 09:57:21 +0000 From: "Kristi Sarap - RA" To: =?utf-8?Q?K=C3=A4rolin_Jenas_-_RA?= References: In-Reply-To: Subject: =?utf-8?Q?Ed:_Meditsiiniuudised_p=C3=A4rivad?= Date: Tue, 5 May 2026 12:57:14 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_006E_01DCE3A1.3B998970" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQENhfB1LAc+zU3EhG+z2v1RMYkRCwIvHHXj Authentication-Results: spf=pass (sender IP is 13.93.42.39) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: X-MS-Exchange-Organization-Network-Message-Id: 9f044cb1-babc-46c9-55c7-08deaa8cb322 X-MS-Exchange-Organization-AuthSource: GV1PR02MB8353.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Transport-EndToEndLatency: 00:00:08.2304307 X-MS-Exchange-Processed-By-BccFoldering: 15.20.9870.020 Content-Language: et received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 13.93.42.39 as permitted sender) receiver=protection.outlook.com; client-ip=13.93.42.39; helo=westeu12-emailsignatures-cloud.codetwo.com; pr=C x-ms-exchange-organization-originalclientipaddress: 146.255.183.65 x-ms-exchange-organization-originalserveripaddress: 10.167.16.57 acceptlanguage: en-GB, en-US X-OlkEid: 000000004C30E2D3CD34B4428531CBEB8A7CAB89070034AD76187591974DBF6C4F76951C873A0100020000000000B04CDEF8D3227A448511457FBBCE9C8700000000089300004E0E2445DE10A9438AC5EA94EE615218 X-MS-Exchange-Organization-SCL: 1 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthMechanism: 04 x-ms-traffictypediagnostic: GV1PR02MB8353:EE_|AM7PPF718F66E3E:EE_|AM1PEPF000252DF:EE_|PAWPR02MB11137:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: 9f044cb1-babc-46c9-55c7-08deaa8cb322 X-MS-Exchange-AtpMessageProperties: SA X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|39142699007|31052699007|366016|22082099003|56012099003|18002099003|8096899003|55112099003|41050700001; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV1PR02MB8353.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(39142699007)(31052699007)(366016)(22082099003)(56012099003)(18002099003)(8096899003)(55112099003)(41050700001);DIR:INT; X-Exchange-RoutingPolicyChecked: RPPbpoZf2YXsz6hLGZlYPOPGCvNlKLEokZgQF3G2xv3OR8dQSkuiStgpqB5v1flFvLYDxtaICuhIq2Pgp2NGYB0xp5pIut1pVhIPR6HsX9o1SQP0YB8Mmkl4B22t8jcD2LwyFgkOjLdi9CdgXfwsz14hanNX9gzYOzPe+x+PnTGec7cRkyMMDRcVicS6rp49gro1+5NiPd35lIsrnpfV+Zp8EiBS8GsHUvpcE+UhKOXIOKRAwjDHthaQs4E3RjjkjFD/pQRArpD/P8x5WLeKa1NuRBdr19H4bbZx4TUwI9g/VVSVBZRcRSvpNEHNxBWVs0MgLBU71fWiwUs7Nd11rQ== X-MS-Exchange-Transport-CrossTenantHeadersStamped: PAWPR02MB11137 X-MS-Exchange-Transport-CrossTenantHeadersStamped: AM7PPF718F66E3E X-OrganizationHeadersPreserved: AM7PPF718F66E3E.eurprd02.prod.outlook.com X-CodeTwo-MessageID: 826a2712-e348-44ba-9564-acad8e7ff927.20260505095720@westeu12-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-MS-Exchange-Organization-ExpirationStartTime: 05 May 2026 09:57:21.0704 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-EOPAttributedMessage: 0 X-CrossPremisesHeadersPromoted: AM1PEPF000252DF.eurprd07.prod.outlook.com X-CrossPremisesHeadersFiltered: AM1PEPF000252DF.eurprd07.prod.outlook.com X-MS-Exchange-Transport-CrossTenantHeadersStripped: AM1PEPF000252DF.eurprd07.prod.outlook.com X-MS-PublicTrafficType: Email X-OriginatorOrg: m1wmgpm3xrpm87txzdfw82by7.smtp.codetwo.online X-MS-Office365-Filtering-Correlation-Id-Prvs: 297b4fa9-4f44-4924-cf5f-08deaa8caf11 X-Microsoft-Antispam: BCL:0;ARA:13230040|366016|39142699007|31052699007|82310400026|35042699022|8096899003|55112099003|56012099003|18002099003|22082099003|41050700001; X-Forefront-Antispam-Report: CIP:13.93.42.39;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu12-emailsignatures-cloud.codetwo.com;PTR:westeu12-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(366016)(39142699007)(31052699007)(82310400026)(35042699022)(8096899003)(55112099003)(56012099003)(18002099003)(22082099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 05 May 2026 09:57:20.9222 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 9f044cb1-babc-46c9-55c7-08deaa8cb322 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[13.93.42.39];Helo=[westeu12-emailsignatures-cloud.codetwo.com] X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-AuthSource: GV1PR02MB8353.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 authentication-results-original: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-05-05T09:57:13.254Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; This is a multipart message in MIME format. ------=_NextPart_000_006E_01DCE3A1.3B998970 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit _____ Saatja: Margot Vent Saadetud: teisipäev, 5. mai 2026 09:36 Adressaat: Kristi Sarap - RA Teema: Meditsiiniuudised pärivad Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere, Kristi!Dr Diana Ingerainen esitas eile ravimiseaduse muudatuse, et õed saaks osaleda uusi ravimeid tutvustavatel koolitustel, mida korraldavad vastava müügiloaga ravimfirmad. Kas oleks võimalik saada kelleltki teist kommentaari, on sellest ka varem räägitud ja kuidas amet sellesse muudatusse suhtuks? Tagasisidet ootama jäädes Margot mu.ee-st ------=_NextPart_000_006E_01DCE3A1.3B998970 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable

Saatja: Margot Vent = <Margot.Vent@aripaev.ee>
Saadetud: teisip=C3=A4ev, 5. mai 2026 09:36
Adressaat: Kristi Sarap - RA = <kristi.sarap@ravimiamet.ee>
Teema: Meditsiiniuudised p=C3=A4rivad
 

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Tere, Kristi!=E2=80=8B

Dr Diana Ingerainen esitas eile ravimiseaduse muudatuse, et =C3=B5ed = saaks osaleda uusi ravimeid tutvustavatel koolitustel, mida korraldavad = vastava m=C3=BC=C3=BCgiloaga ravimfirmad. 

Kas oleks v=C3=B5imalik saada kelleltki teist kommentaari, on sellest ka = varem r=C3=A4=C3=A4gitud ja kuidas amet sellesse muudatusse = suhtuks?

Tagasisidet ootama j=C3=A4=C3=A4des

Margot 
mu.ee-st

------=_NextPart_000_006E_01DCE3A1.3B998970--